Vistagen Therapeutics Downgraded to Hold with Target Price Slashed 94% to $0.90
AI Summary1 min read
TL;DR
Jefferies downgraded Vistagen Therapeutics from Buy to Hold and cut its target price from $15.00 to $0.90, signaling a cautious outlook on the stock's future performance.
Tags
VistagenVistagen Therapeuticsstock downgradetarget priceJefferiesinvestment strategy
Jefferies downgraded Vistagen Therapeutics (VTGN) from Buy to Hold, slashing the target price from $15.00 to $0.90. The company's rating shift and drastic price decrease indicate a more conservative approach towards its future performance. Investors should be aware of this development as it may influence trading strategies and stock performance for VTGN.
